Overview
Virtual Event
Click Here to View the Program in Japanese
Click Here to View the Program in English
Taking the theme “Beyond Innovation”, the Japan Annual Meeting 2020 will bring together academia, regulators, industry professionals, and patients from across the world to exchange information and discuss the latest trends in the discovery, development, and lifecycle management of pharmaceuticals, medical devices, and related products.
This is the largest event in the DIA Japan annual calendar and features more than 60 sessions on topics ranging from Risk Management, Patient Engagement and Pharmacovigilance to the 30th anniversary of ICH, the future of Healthcare, and the COVID-19 pandemic. Our hugely popular PMDA Town Hall DIAmond session also makes a return to the program.
This year’s Meeting will be held entirely online through a fully integrated platform offering live and on-demand content, live Q&A sessions with speakers, group and 1-2-1 networking opportunities and much more! Breaking walls and boundaries, the virtual platform will enable you to join the event from wherever you may be and to connect with fellow professionals from across the world.
We look forward to seeing you there!
Event Concept
In recent years, while the fourth industrial revolution progresses, various new initiatives on innovation, which lead to novel values or substantial changes in healthcare product research & development, have begun by creation and usage of brand new ideas and technologies such as artificial intelligence, big data and utilization of medical and genome information.
There are two categories of innovation; disruptive innovation, which could bring drastic changes in the way we think and do things, and sustaining innovation, which could bring an improvement of products and services by using technology refinement in the existing platform. Important thing is that; we need to actively learn the cutting-edge technologies supporting various innovations, continuously think how our day-to-day work is going to change in the future, and create skills and mindset which could cope with various new changes. Meanwhile, we would like to encourage key stakeholders in healthcare to step back and think about if the values and changes brought by such innovations would really contribute to health and welfare of patients.
As the theme for the 17th DIA Japan Annual Meeting 2020, we chose the phrase “Beyond Innovation”. With DIA’s mission to provide a neutral platform for discussion, we would like to convene various stakeholder in Industry, government, academia as well as patients, to learn new technologies and initiatives, and discuss what we should eventually aiming for, leading to further facilitate the progress of healthcare innovation.
Program Committee
-
Yuji Kumagai, MD, PhD • Professor, Clinical Research Center
Kitasato University Hospital, Japan -
Keiichi Inaizumi, MSc • Japan Clinical Project Manager, Clinical Operations and Compliance 1
Pfizer R&D Japan, Japan -
Taro Amagasaki, PhD • Head, Analytics Japan
Novartis Pharma K.K., Japan -
Nobuyuki Hanamura, PhD, MBA • Senior Director, Clinical Development Strategy & Solutions
Japan -
Toshiko Ishibashi, PhD, RN • Clinical Operation I, Clinical Operation Management
Ono Pharmaceutical Co., Ltd., Japan -
Kazuhiko Ishida, MSc, RPh • Director, Risk Management, Pharmacovigilance
Astellas Pharma Inc., Japan -
Yayoi Kitawaki, MS • Senior Japan Program Head, Oncology Development Unit, Japan Development
Novartis Pharma K.K., Japan -
Yoshiko Komuro, PhD • Inspector Director, Office of Non-clinical and Clinical Compliance
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Takashi Moriya, PhD, MBA • Director
Janssen Pharmaceutical K.K., Japan -
Sumimasa Nagai, MD, PhD • Senior Assistant Professor, Translational Research Center
The University of Tokyo Hospital, Japan -
Shinichi Nishiuma, MD • Executive Director, Head of Medical Affairs, Japan
Celgene K.K., Japan -
Mika Ogasawara • Quality Lead, Biometrics and Data Management
Pfizer R&D Japan, Japan -
Goshi Ozawa, MS • Exective officer, RWD dept.
Real World Data Co., Japan -
Keiko Tsumori • Associate Director, Medical Writing, Regulatory Affairs Area, Japan Development
MSD K.K., Japan -
Junichi Nishino, MSc, RPh • Director, Medical Regulatory Affairs Department
Otsuka Pharmaceutical Co., Ltd., Japan -
Hironobu Saito, PhD • Corporate Officer /Head of Medical Affairs Div.
Daiichi Sankyo Co., Ltd., Japan -
Junko Sato, PhD • Director, Office of International Programs
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Takashi Sato, MSc, PMP • Manager, Project Management Group, R&D Planning Department
Kyowa Kirin Co., Ltd., Japan -
Atsushi Tsukamoto, PhD, MSc •
Daiichi Sankyo Company, Limited, Japan
